Perspective Therapeutics, Inc.
CATX
$3.46
-$0.22-5.98%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.20% | 54.75% | -165.63% | -- | -- |
| Total Depreciation and Amortization | 0.14% | -48.12% | 110.91% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.40% | -94.87% | 1,555.83% | -- | -- |
| Change in Net Operating Assets | 83.04% | 52.93% | -169.94% | -- | -- |
| Cash from Operations | 7.55% | 18.88% | -890.43% | 137.81% | -164.28% |
| Capital Expenditure | 77.96% | 68.14% | 50.82% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 681.96% | 99.27% | -517,912.50% | -- | -- |
| Cash from Investing | 176.62% | 95.98% | -366.09% | -802.49% | 93.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -8.33% | 25.00% | -- | -- |
| Issuance of Common Stock | -98.55% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.68% | 2,790.72% | -45.06% | -99.49% | -26.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.42% | 89.58% | -540.42% | -123.43% | -17.30% |